Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7161 - 7168 of 12009 results
March Preparedness: Inadequate Employee Training May Cause Even the Best Employers to Suffer an Upset
March 21, 2017| Blog| Viewpoint
New York Medical Society Warns Providers to Avoid Percentage-Based Fees
March 21, 2017| Blog| Viewpoint
Wyden’s C-THRU Act – Publicizing PBM Rebate Data
March 21, 2017| Blog| Viewpoint
Federal Circuit Invalidates Claim to Generating “Financial Risk” Reports
March 21, 2017| Blog| Viewpoint
Supreme Court Shuts the Door on Patent Laches
March 21, 2017| Blog| Viewpoint
An Arbitration Agreement That Attempts to Skew a Statutory Arbitration Scheme Is Void as Against Public Policy
March 20, 2017| Blog| Viewpoint
Upcoming Webinar: AEE’s State of Advanced Energy: Markets, Trends, Jobs (March 30)
March 20, 2017| Blog| Viewpoint
More Broken Privacy Promises from Upromise: Key Takeaways From Upromise’s Latest Settlement with the FTC
March 20, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|